RCT: Survival with Cemiplimab in recurrent cervical cancer.
11 Feb, 2022 | 08:36h | UTCSurvival with Cemiplimab in Recurrent Cervical Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Cemiplimab Prolongs Survival in Recurrent Cervical Cancer – HealthDay